Sionna Therapeutics, Inc. (NASDAQ: SION) is a Healthcare company (Biotechnology) with a market capitalization of $139M. The Maz Rating grades it against the other companies in its sector.
Sionna Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.07, Sionna Therapeutics, Inc. trades at 0.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -39.8%, return on invested capital of -46.0% and a free cash flow yield of -73.1%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 13.92. Over the past 52 weeks the share price ranged from $2.99 to $54.97, with a beta of 1.22.
Sionna Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 3 Buy, 4 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Sionna Therapeutics, Inc. (SION) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 108.2% / 30% · Interest income / Revenue 240700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 97.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 240700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 97.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 240700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.60% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 240700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 85.3% / 33.33% · (Cash+Recv) / Total Assets 85.3% / 33.33% · Interest income / Revenue 240700000.0% / 5% | Fail |
No. As of September 2026, Sionna Therapeutics, Inc. (SION) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Sionna Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 240700000.0% of each dividend: Sionna Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.